Furthermore, a greater proportion of new users of DPP-4i had cardiovascular disease at baseline as compared to new users of SGLT-2i and GLP-1 RA, although SGLT-2i2 and GLP-1 RA [20] have a greater cardioprotective effect and are indicated for use in patients with type 2 diabetes at elevated cardiovascular risk [2]. The gene discussed is GLP1R; the disease is type 2 diabetes mellitus.